美国食品药品监督管理局批准首款靶向前列腺特异性膜抗原的正电子发射断层显像药物。 - Suppr

Suppr

超能文献

FDA Approves First PSMA-Targeted PET Drug.

出版信息

J Nucl Med. 2021 Feb;62(2):11N.

PMID:33468545

Abstract

摘要

相似文献

FDA Approves First PSMA-Targeted PET Drug.美国食品药品监督管理局批准首款靶向前列腺特异性膜抗原的正电子发射断层显像药物。

J Nucl Med. 2021 Feb;62(2):11N.

FDA approves first PSMA-targeted radiopharmaceutical.美国食品药品监督管理局批准首款靶向前列腺特异性膜抗原的放射性药物。

Nat Rev Drug Discov. 2022 May;21(5):327. doi: 10.1038/d41573-022-00067-5.

A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.一种高亲和力 [(18)F]-标记的膦酰胺肽拟态 PSMA 靶向抑制剂，用于前列腺癌的 PET 成像。

Nucl Med Biol. 2015 Oct;42(10):780-7. doi: 10.1016/j.nucmedbio.2015.06.003. Epub 2015 Jun 9.

Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.原发性临床试验方案，一项前瞻性、多中心、横断面研究，旨在评估镓 68 前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描对多参数磁共振成像在前列腺癌诊断中的附加诊断价值。

BJU Int. 2020 Apr;125(4):515-524. doi: 10.1111/bju.14999. Epub 2020 Feb 12.

Diagnostic Role of F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review.F-PSMA-1007 PET/CT在前列腺癌分期中的诊断作用：一项系统评价

Diagnostics (Basel). 2021 Mar 19;11(3):552. doi: 10.3390/diagnostics11030552.

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.分子影像报告与数据系统（MI-RADS）：具有治疗诊断意义的靶向放射性示踪剂的通用框架。

Ann Nucl Med. 2018 Oct;32(8):512-522. doi: 10.1007/s12149-018-1291-7. Epub 2018 Aug 14.

More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence.前列腺特异性膜抗原靶向 PET 成像在前列腺癌复发中的应用。

Curr Opin Urol. 2020 Sep;30(5):635-640. doi: 10.1097/MOU.0000000000000793.

Detection Efficacy of F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.F-PSMA-1007 PET/CT 在 251 例前列腺癌根治术后生化复发患者中的检测效能。

J Nucl Med. 2019 Mar;60(3):362-368. doi: 10.2967/jnumed.118.212233. Epub 2018 Jul 24.

Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.将前列腺特异性膜抗原（PSMA）靶向正电子发射断层显像（PET）成像纳入用于检测具有临床意义的前列腺癌的手段之中。

Curr Opin Urol. 2018 Nov;28(6):493-498. doi: 10.1097/MOU.0000000000000549.

引用本文的文献

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.胃泌素释放肽受体（GRPR）与前列腺特异性膜抗原（PSMA）：前列腺癌进展过程中的表达谱显示了靶向GRPR的诊疗方法的附加价值。

Front Oncol. 2023 Aug 31;13:1199432. doi: 10.3389/fonc.2023.1199432. eCollection 2023.

A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.基于 PSMA PET 衍生的器官特异性肿瘤体积的前列腺癌预后风险评分。

Radiology. 2023 May;307(4):e222010. doi: 10.1148/radiol.222010. Epub 2023 Apr 18.

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.三分之一的恶性胸膜间皮瘤表现出高水平的 MSLN 或 CXCR4 的免疫组织化学表达，这表明它们是内放射治疗的潜在候选者。

Int J Mol Sci. 2023 Mar 28;24(7):6356. doi: 10.3390/ijms24076356.

Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines.基于 Ga-PSMA PET/CT 的前列腺床根治性前列腺切除术后复发图谱：挽救性放疗勾画指南的临床意义。

J Nucl Med. 2023 Jun;64(6):902-909. doi: 10.2967/jnumed.122.265025. Epub 2023 Feb 9.

PSMA-based F-DCFPyL PET: a better choice than multiparametric MRI for prostate cancer diagnosis?基于前列腺特异性膜抗原（PSMA）的F-DCFPyL正电子发射断层扫描（PET）：在前列腺癌诊断中比多参数磁共振成像（MRI）是更好的选择吗？

Am J Nucl Med Mol Imaging. 2022 Dec 15;12(6):195-200. eCollection 2022.

PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study.PSMA PET用于评估去势抵抗性前列腺癌患者的肝转移：一项多中心回顾性研究

Cancers (Basel). 2022 Nov 18;14(22):5680. doi: 10.3390/cancers14225680.

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?前列腺特异性膜抗原放射性配体摄取作为实体肿瘤新生血管生成的生物标志物：诊断还是治疗诊断因素？

Cancers (Basel). 2022 Aug 21;14(16):4039. doi: 10.3390/cancers14164039.

The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence.多模态 PET/CT 成像在检测前列腺癌生化复发中的价值。

Front Endocrinol (Lausanne). 2022 May 27;13:897513. doi: 10.3389/fendo.2022.897513. eCollection 2022.

Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.用于前列腺癌治疗的多功能放射性/免疫诊疗工具的开发与功能表征

Cancers (Basel). 2022 Apr 14;14(8):1996. doi: 10.3390/cancers14081996.

A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.基于单域抗体的抗 PSMA 重组免疫毒素具有前列腺癌治疗的特异性和疗效。

Int J Mol Sci. 2021 May 23;22(11):5501. doi: 10.3390/ijms22115501.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验